Investigators identified that PCK1 was a pivotal regulator in therapy-induced neuroendocrine differentiation of prostate cancer through a LIF/ZBTB46-driven glucose metabolism pathway.
[British Journal of Cancer]
Sorry, but the selected Zotpress account can't be found.